Stocktoria

Rapport Therapeutics, Inc. RAPP

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2024-06-07

Rapport Therapeutics, Inc. statistics & valuation

Market cap$1.9B
P / B4.0×
Return on equity-23.0%
Return on capital-25.4%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
202320242025
Operating margin (%)
202320242025
Return on equity (%)
-25.60% -23.00% 202320242025
Shares outstanding
4.2M 36.6M 47.8M 202320242025
Net debt ($)
202320242025
Share buybacks ($)
202320242025
Return on assets (%)
-22.40% -24.90% -21.80% 202320242025
Free cash flow margin (%)
202320242025
Debt / equity (×)
202320242025
EPS ($)
-$23.10 -$3.78 -$2.86 202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023
Return on assets-21.8%-24.9%-22.4%
Return on equity-23.0%-25.6%135.7%
Current ratio26.1735.3417.14

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.